

The Impact of Aspirin on the Risk of Preeclampsia at Different Gestational Weeks

Hang GAO, Zhiqiao HUANG, Yin WU, Zhifeng MO*

*Department of Obstetrics, Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong Province, China, 518028. * Corresponding Author, Department of Emergency and Disaster Medical Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong Province, China, 518000 .Email: mozhf3@mail.sysu.edu.cn. <https://orcid.org/0000-0002-9273-003X>.*

Abstract

Preeclampsia is a common complication during pregnancy that significantly affects both maternal and fetal health. In recent years, aspirin has garnered widespread attention as an important medication for preventing preeclampsia. This review examines the effects of aspirin administration at various gestational stages on the risk of developing preeclampsia, analyzing relevant research findings and theoretical foundations. Additionally, the review discusses the optimal timing and dosage of aspirin in this context. Through a comprehensive analysis of existing literature, this article aims to provide guidance for clinical practice in the prevention of preeclampsia.

Keywords Preeclampsia; Aspirin; Gestational Weeks; Risk of Occurrence; Prevention

To Cite This Article Hang GAO, et al. (2024). The Impact of Aspirin on the Risk of Preeclampsia at Different Gestational Weeks. *Medical Research*, 6(3), 67-78. <https://doi.org/10.6913/mrhk.060307>

Medical Research, ISSN 2664-0333 (print), ISSN 2664-0341 (online), DOI 10.6913/mrhk, a bimonthly, founded on 2018, Indexed by CNKI, Google Scholar, AIRITI, Scilit, CrossRef, Elsevier PlumX, etc., published by Creative Publishing Co., Limited. Email: wtocom@gmail.com, <https://mrhk.cc>, <https://cpcl.hk>.

1 Introduction

1.1 Preeclampsia: Definition and Clinical Manifestations

Preeclampsia is a pregnancy-specific disorder characterized by the onset of hypertension and proteinuria after 20 weeks of gestation. Clinically, it presents with symptoms such as severe headaches, visual disturbances, abdominal pain, and edema. The condition can escalate to eclampsia, which involves seizures and poses significant risks to both mother and fetus, potentially leading to maternal and fetal mortality if left untreated^[1]. The pathophysiology of preeclampsia is complex, involving placental dysfunction, maternal immune response, and cardiovascular changes. Understanding these clinical manifestations is crucial for timely diagnosis and management, as early intervention can mitigate severe complications.

1.2 Epidemiology of Preeclampsia

Epidemiologically, preeclampsia affects approximately 2–8% of pregnancies globally, with a higher prevalence observed in certain populations, such as those with a history of hypertension or obesity^[2]. The incidence is also influenced by factors such as maternal age, with advanced maternal age correlating with a higher risk of severe manifestations of the disease^[3]. Additionally, the condition is more prevalent in first-time pregnancies and among women with a family history of preeclampsia. The rising rates of preeclampsia are concerning, particularly in light of increasing maternal age and obesity rates in many countries, underscoring the need for effective preventive strategies.

1.3 Aspirin as a Preventive Measure

Aspirin has been widely studied for its potential role in preventing preeclampsia, particularly in high-risk populations. Low-dose aspirin is thought to work by inhibiting platelet aggregation and improving uteroplacental blood flow, thereby reducing the risk of placental ischemia, a key contributor to preeclampsia^[4]. Current guidelines recommend the use of low-dose aspirin for women at high risk of developing preeclampsia, starting as early as the first trimester^[5]. The research surrounding the efficacy and safety of aspirin in this context is critical, as it could lead to improved maternal and fetal outcomes.

1.4 Purpose of the Review

The purpose of this review is to evaluate the current evidence regarding the effectiveness of low-dose aspirin in preventing preeclampsia, particularly in high-risk populations. By synthesizing the latest findings, this review aims to highlight the importance of early intervention and the potential for aspirin to serve as a valuable tool in the management of preeclampsia, ultimately contributing to better health outcomes for mothers and their infants^[6].

2 Aspirin as a Therapeutic Approach in the Prevention and Management of Preeclampsia

2.1 Pathogenesis and Risk Factors of Preeclampsia

Preeclampsia (PE) is a complex pregnancy-related disorder characterized by hypertension and proteinuria, affecting approximately 5–8% of pregnancies globally. The pathogenesis of PE is multifaceted, involving maternal, placental, and fetal factors. One key mechanism is the failure of trophoblastic cells to adequately remodel the maternal spiral arteries, leading to placental ischemia and the subsequent release of factors that cause systemic endothelial dysfunction and hypertension. This is further compounded by issues with immune tolerance at the maternal-fetal interface, potentially resulting in an exaggerated inflammatory response that contributes to the clinical manifestations of PE^[7].

Risk factors for developing PE include a history of hypertension, obesity, diabetes, and advanced maternal age. Studies have shown that genetic predispositions, such as polymorphisms in genes related to immune response and endothelial function, may also play a role in the development of PE^[8]. Furthermore, environmental factors such as dietary habits and exposure to toxins have been implicated in the pathogenesis of this condition^[9]. The interplay between these factors is complex, suggesting that a multifactorial approach is necessary to fully understand and potentially prevent PE.

Recent research has also highlighted the role of microRNAs and long non-coding RNAs in the regulation of gene expression during placentation, which may contribute to the pathophysiology of PE^[10]. Additionally, elevated levels of inflammatory markers, such as S100A9, have been associated with increased secretion of soluble endoglin and IL-1 β , further exacerbating hypertension through the activation of the NLRP3 inflammasome^[11]. Understanding these mechanisms and risk factors is crucial for developing effective prevention and management strategies for PE.

2.2 Mechanisms of Aspirin in Preventing Preeclampsia

Aspirin has been widely studied for its role in the prevention of preeclampsia, particularly in high-risk populations. The primary mechanism by which aspirin exerts its protective effects is through the inhibition of platelet aggregation and the reduction of thromboxane A₂ synthesis, which subsequently improves uteroplacental blood flow and reduces the risk of placental ischemia^[12]. Low-dose aspirin has been shown to enhance the production of prostacyclin, a potent vasodilator, which counteracts the vasoconstrictive effects of thromboxane^[13].

Moreover, aspirin's anti-inflammatory properties play a significant role in modulating the immune response at the maternal-fetal interface. By reducing the levels of pro-inflammatory cytokines and promoting an anti-inflammatory environment, aspirin may help maintain immune tolerance and prevent the exaggerated inflammatory response that characterizes PE^[14]. Recent studies have also indicated that aspirin may influence the expression of genes involved in trophoblast cell survival and apoptosis, thereby promoting healthy placentation and reducing the

risk of PE^[15].

The timing and dosage of aspirin administration are critical factors influencing its effectiveness. Evidence suggests that initiating low-dose aspirin therapy before 16 weeks of gestation can significantly reduce the incidence of PE in women with identifiable risk factors^[16]. Additionally, the combination of aspirin with other therapeutic agents, such as apocyanin, has shown promise in enhancing the protective effects against PE by activating key signaling pathways^[17]. Overall, understanding the multifaceted mechanisms of aspirin in the prevention of preeclampsia is vital for optimizing treatment strategies and improving maternal and fetal outcomes.

2.3 Current Research Status of Aspirin Use at Different Gestational Weeks

2.3.1 Effects of Aspirin Use in Early Pregnancy

Early pregnancy is a critical period during which the risk of developing complications such as preeclampsia can be significantly influenced by pharmacological interventions. Numerous studies have investigated the effects of low-dose aspirin (LDA) during this stage. Research indicates that initiating aspirin therapy before 11 weeks of gestation can lead to a notable reduction in the incidence of preeclampsia among high-risk populations, particularly in women with a history of hypertensive disorders in previous pregnancies or those with chronic hypertension^{[18][19]}. The mechanisms by which aspirin exerts its protective effects include modulation of placental blood flow and reduction of inflammatory markers, which are often elevated in preeclampsia^{[20][21]}. A meta-analysis has suggested that early administration of aspirin not only lowers the risk of preeclampsia but also improves perinatal outcomes, including reduced rates of preterm birth and low birth weight^[22]. However, the optimal timing and dosage remain subjects of ongoing research, with some studies advocating for individualized approaches based on specific risk factors^[23]. (Figure 1)

2.3.2 Risk Assessment in Mid-Pregnancy

As pregnancy progresses into the mid-gestational period, the assessment of risks associated with continued aspirin use becomes essential. During this stage, the potential benefits of aspirin must be weighed against possible adverse effects. Current literature suggests that the use of low-dose aspirin in mid-pregnancy is generally considered safe, but careful monitoring is required, especially for women with preexisting conditions such as diabetes or hypertension^{[24][19]}. Studies have shown that mid-pregnancy is characterized by significant physiological changes, including alterations in hemodynamics and placental function, which may influence the efficacy of aspirin^[25]. Additionally, the risk of bleeding complications, particularly in women with certain coagulopathies or those undergoing invasive procedures, necessitates a thorough risk assessment^[26]. Thus, while aspirin continues to be recommended for high-risk populations, clinicians are advised to evaluate individual risk profiles and adjust treatment protocols accordingly^[27]. (Figure 2)




Figure 1: Forest plot of outcomes by ethnicity and race, High-Risk Aspirin (HRA) study. There was no significant impact of aspirin in the prevention of preeclampsia among subjects at high risk, including when stratified by race or ethnicity. CI, confidence interval. Tolcher et al. Impact of ethnicity and race on aspirin for preeclampsia prevention. AJOG MFM 2020.

2.3.3 Safety and Efficacy in Late Pregnancy

In late pregnancy, the safety and efficacy of aspirin use require careful consideration, especially as the focus shifts toward managing labor and delivery outcomes. Research indicates that the continuation of low-dose aspirin is generally safe up to the third trimester, but its use should be individualized based on maternal and fetal health status^[28]. Late pregnancy is often associated with increased risks of placental abruption and postpartum hemorrhage, raising concerns about the potential for aspirin to exacerbate these conditions^[22]. However, evidence suggests that the benefits of aspirin in preventing preeclampsia and improving placental perfusion may outweigh the risks in selected populations^[27]. Moreover, ongoing studies are exploring the impact of aspirin on long-term maternal and neonatal outcomes, with preliminary findings indicating that appropriate use may lead to favorable results in terms of maternal blood pressure management and fetal growth parameters^{[24][20]}. Thus, while late pregnancy presents unique challenges, aspirin remains a valuable tool in the management of high-risk pregnancies when used judiciously.




Figure 2: Forest plot of outcomes by ethnicity and race, Low-Risk Aspirin (LRA) study. The efficacy of aspirin for prevention among subjects at a low risk of the occurrence of preeclampsia was observed to be significant only among non-Hispanic white women and not among non-Hispanic black or Hispanic women. CI, confidence interval. Tolcher et al. Impact of ethnicity and race on aspirin for preeclampsia prevention. *AJOG MFM* 2020

2.4 Current Research Status of Aspirin in the Prevention of Preeclampsia (PE)

The use of low-dose aspirin in the prevention of preeclampsia (PE) has garnered significant attention in both domestic and international research communities. Preeclampsia is a pregnancy complication characterized by high blood pressure and potential damage to other organ systems, particularly the liver and kidneys. The pathophysiology of PE is complex, involving placental dysfunction, inflammatory processes, and endothelial dysfunction. Recent studies suggest that low-dose aspirin may help mitigate these risks by improving placental blood flow and reducing systemic inflammation. For example, a study conducted in China indicated that administering aspirin at a dosage of 75 mg daily effectively reduces the incidence of preeclampsia in high-risk pregnancies, demonstrating its potential as a preventive measure in clinical settings^[29].

Internationally, numerous studies have examined the efficacy of low-dose aspirin in preventing PE. One notable study developed a prediction model for first-trimester preterm preeclampsia, highlighting the importance of early intervention with low-dose aspirin in at-risk populations^[30]. Additionally, a systematic review emphasized aspirin's role in reducing the risk of PE, particularly in women with a history of the condition or other risk factors such as obesity and chronic hypertension^[31]. The International Federation of Gynecology and Obstetrics (FIGO) has also published guidelines advocating the use of low-dose aspirin in high-risk pregnancies, underscor-

ing its significance in contemporary obstetric care^[32].

Furthermore, research into the biological mechanisms through which aspirin exerts its effects on placental health has advanced. Phosphoproteomic studies have provided insights into how aspirin may regulate apoptotic pathways in preeclampsia-like placental models, suggesting a direct impact on placental cellular health^[15]. These findings underscore the clinical implications of aspirin use and highlight the need for further exploration into its pharmacological mechanisms.

In conclusion, the current landscape of research indicates a promising role for low-dose aspirin in the prevention of preeclampsia. With growing evidence from both domestic and international studies, aspirin appears to be an essential component in managing high-risk pregnancies. Ongoing clinical trials and real-world studies will be crucial in further elucidating the optimal use of aspirin for PE prevention and its long-term effects on maternal and fetal outcomes.

2.5 Recommendations from Various National Guidelines on Aspirin for Preeclampsia Prevention

Aspirin has emerged as a key intervention in the prevention of preeclampsia, with various national guidelines endorsing its use for high-risk pregnant women. The American College of Obstetricians and Gynecologists (ACOG) recommends low-dose aspirin (81 mg) starting at 12 weeks of gestation for women with a history of preeclampsia, chronic hypertension, or multiple gestations, among other risk factors. Similarly, the National Institute for Health and Care Excellence (NICE) in the UK supports aspirin prophylaxis for women identified as high-risk, emphasizing its role in reducing the incidence of preeclampsia and its associated complications. In Australia, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) also advocates for the use of low-dose aspirin in their guidelines, aligning with evidence suggesting its efficacy in high-risk populations. Recent studies underscore the importance of educational interventions to improve adherence to aspirin therapy among pregnant women, highlighting a gap in knowledge that could affect clinical outcomes^[33]. Overall, the consensus across these guidelines reflects a growing recognition of aspirin's potential benefits in preventing preeclampsia, though variations in recommendations underscore the need for tailored approaches based on individual risk assessments.

2.6 Challenges in Clinical Practice and Future Research Directions

The implementation of aspirin for preeclampsia prevention faces several challenges in clinical practice. One significant issue is the underutilization of aspirin prophylaxis, particularly in underserved populations. A study conducted in Sub-Saharan Africa revealed a missed opportunity for aspirin prophylaxis, indicating systemic barriers that prevent high-risk women from receiving appropriate care^[34]. Additionally, variability in guidelines and the lack of standardized protocols can lead to confusion among healthcare providers regarding when and how to initiate aspirin therapy. The need for effective strategies to improve the utilization of aspirin in high-risk cohorts is evident, as demonstrated by recent research aimed at enhancing adherence through educational

initiatives^[35].

2.6.1 Limitations of Existing Research

Despite the growing body of evidence supporting aspirin's role in preeclampsia prevention, existing research has notable limitations. Many studies are observational and may be subject to biases, such as selection bias, which can affect the reliability of the findings. Furthermore, there is a lack of consensus on the optimal dosage and timing for aspirin initiation, with some studies suggesting that higher doses may be more effective than lower ones^[36]. Additionally, the generalizability of findings is often limited to specific populations, raising questions about the applicability of results across diverse demographic groups. These limitations highlight the necessity for more robust, randomized controlled trials to clarify the role of aspirin in various at-risk populations.

2.6.2 Future Research Needs and Potential Directions

Future research should focus on addressing the gaps identified in existing studies, particularly through well-designed randomized controlled trials that explore the efficacy and safety of different aspirin dosages and regimens. Investigating the biological mechanisms underlying aspirin's protective effects against preeclampsia could also provide valuable insights that inform clinical practice. Moreover, research should prioritize understanding the socio-economic and cultural factors that influence adherence to aspirin therapy among high-risk populations, as this knowledge could guide the development of tailored interventions. The incorporation of technology, such as mobile health applications, may also enhance patient education and compliance^[37].

2.6.3 Development and Promotion of Clinical Guidelines

The formulation and dissemination of clinical guidelines for aspirin use in preeclampsia prevention must be a collaborative effort involving obstetricians, researchers, and public health officials. Guidelines should be regularly updated to reflect new evidence and should emphasize the importance of individualized risk assessment in determining aspirin therapy. Furthermore, strategies to promote awareness and education among healthcare providers and patients are crucial for improving adherence to guidelines. Engaging stakeholders in the guideline development process can enhance acceptance and implementation in clinical settings. Ultimately, the successful integration of aspirin prophylaxis into routine prenatal care hinges on a concerted effort to address the challenges identified and to foster an evidence-based approach to managing preeclampsia risk^[38].

3 Conclusion

In summary, the effectiveness of aspirin in the prevention of preeclampsia has been well-documented, with numerous studies highlighting its role in reducing the incidence of this serious pregnancy complication. Aspirin, particularly in low doses, has emerged as a critical intervention for high-risk populations, such as those with a history of preeclampsia, chronic hypertension, or other

relevant risk factors. While the benefits of aspirin in mitigating the risk of preeclampsia are evident, the timing of administration is equally crucial.

The analysis of risks and benefits associated with aspirin use at various gestational ages reveals a nuanced landscape. Early initiation of aspirin therapy—ideally before 16 weeks of gestation—has shown the most promise in reducing the risk of preeclampsia. However, the potential side effects, such as gastrointestinal bleeding or allergic reactions, must also be carefully considered in the risk-benefit assessment. This highlights the need for personalized treatment approaches, taking into account individual patient histories and risk profiles.

As we move forward, it is essential to balance the various findings from existing research while acknowledging the heterogeneity of study populations. The variations in methodology, dosages, and gestational timing across studies can lead to conflicting results. Future research should focus on large-scale, multicenter trials that standardize these variables to provide clearer guidelines. Additionally, the exploration of biomarkers that could predict which patients will benefit most from aspirin therapy may enhance clinical decision-making.

In clinical practice, it is imperative to integrate these findings into patient care, ensuring that healthcare providers are well-informed about the potential benefits of aspirin in preventing preeclampsia while also considering the associated risks. Education on the importance of early screening and personalized care pathways will empower practitioners to make informed decisions in collaboration with their patients.

In conclusion, while aspirin represents a promising strategy for the prevention of preeclampsia, ongoing research and careful consideration of individual risk factors will be essential in optimizing outcomes for pregnant individuals. The path forward should prioritize clarity in research findings and a commitment to evidence-based practice, ultimately aiming for improved maternal and fetal health.

Article History

Received: May 29, 2024 **Accepted:** June 25, 2024 **Published:** September 30, 2024

References

- [1] Bouter AR, Duvekot JJ. Evaluation of the clinical impact of the revised ISSHP and ACOG definitions on preeclampsia. *Pregnancy Hypertens.* 2020;19:206–211. doi:10.1016/j.preghy.2019.11.011
- [2] Simard JF, Rossides M, Wikström AK, Falasinnu T, Palmsten K, Arkema EV. Evidence of under-reporting of early-onset preeclampsia using register data. *Paediatr Perinat Epidemiol.* 2021;35(5):596–600. doi:10.1111/ppe.12759
- [3] Gilboa I, Kupferminc M, Schwartz A, et al. The Association between Advanced Maternal Age and the Manifestations of Preeclampsia with Severe Features. *J Clin Med.* 2023;12(20):6545. Published 2023 Oct 16. doi:10.3390/jcm12206545
- [4] He G, Chen Y, Chen M, He G, Liu X. Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis. *Medicine (Baltimore).* 2020;99(46):e22801. doi:10.1097/MD.00000000000022801

- [5] Wang Z, Liu D, Dai Y, et al. Elevated Placental microRNA-155 Is a Biomarker of a Preeclamptic Subtype. *Hypertension*. 2023;80(2):370-384. doi:10.1161/HYPERTENSIONAHA.122.19914 <https://pubmed.ncbi.nlm.nih.gov/36>
- [6] Vatish M, Powys VR, Cerdeira AS. Novel therapeutic and diagnostic approaches for preeclampsia. *Curr Opin Nephrol Hypertens*. 2023;32(2):124-133. doi:10.1097/MNH.0000000000000870
- [7] Luo F, Yue J, Li L, Mei J, Liu X, Huang Y. Narrative review of the relationship between the maternal-fetal interface immune tolerance and the onset of preeclampsia. *Ann Transl Med*. 2022;10(12):713. doi:10.21037/atm-22-2287
- [8] Xing Y, Jiang HL, Hou L, Wang X. Expression of ICAM-1 in placental tissues and the association between its gene polymorphisms and pathogenesis of preeclampsia. *Eur Rev Med Pharmacol Sci*. 2020;24(22):11481-11487. doi:10.26355/eurrev_202011_23789
- [9] Xu H, Xie Y, Sun Y, et al. Integrated analysis of multiple microarray studies to identify potential pathogenic gene modules in preeclampsia. *Exp Mol Pathol*. 2021;120:104631. doi:10.1016/j.yexmp.2021.104631
- [10] Ma Y, Hou B, Zong J, Liu S. Potential molecular mechanisms and clinical implications of piRNAs in preeclampsia: a review. *Reprod Biol Endocrinol*. 2024;22(1):73. Published 2024 Jun 24. doi:10.1186/s12958-024-01247-1
- [11] Ozeki A, Oogaki Y, Henmi Y, et al. Elevated S100A9 in preeclampsia induces soluble endoglin and IL-1 β secretion and hypertension via the NLRP3 inflammasome. *J Hypertens*. 2022;40(1):84-93. doi:10.1097/HJH.0000000000002981
- [12] Dutta S, Kumar S, Hyett J, Salomon C. Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during Pregnancy. *Int J Mol Sci*. 2019;20(18):4370. Published 2019 Sep 5. doi:10.3390/ijms20184370
- [13] Gonzalez-Brown VM, Ma'ayeh M, Kniss DA, Cackovic M, Landon MB, Rood KM. Low-dose aspirin increases 15-epi-lipoxins A4 in pregnancies at high-risk for developing preeclampsia. *Pregnancy Hypertens*. 2021;26:75-78. doi:10.1016/j.preghy.2021.09.003
- [14] Guo KM, Li W, Wang ZH, He LC, Feng Y, Liu HS. Low-dose aspirin inhibits trophoblast cell apoptosis by activating the CREB/Bcl-2 pathway in pre-eclampsia. *Cell Cycle*. 2022;21(21):2223-2238. doi:10.1080/15384101.2022.2092814
- [15] Huai J, Li GL, Lin L, Ma JM, Yang HX. Phosphoproteomics reveals the apoptotic regulation of aspirin in the placenta of preeclampsia-like mice. *Am J Transl Res*. 2020;12(7):3361-3375. Published 2020 Jul 15.
- [16] Muldoon KA, McLean C, El-Chaár D, et al. Persisting risk factors for preeclampsia among high-risk pregnancies already using prophylactic aspirin: a multi-country retrospective investigation. *J Matern Fetal Neonatal Med*. 2023;36(1):2200879. doi:10.1080/14767058.2023.2200879
- [17] Ju Y, Feng Y, Hou X, et al. Combined apocyanin and aspirin treatment activates the PI3K/Nrf2/HO-1 signaling pathway and ameliorates preeclampsia symptoms in rats. *Hypertens Pregnancy*. 2022;41(1):39-50. doi:10.1080/10641955.2021.2014518
- [18] Ghazanfarpour M, Sathyapalan T, Banach M, Jamialahmadi T, Sahebkar A. Prophylactic aspirin for preventing pre-eclampsia and its complications: An overview of meta-analyses.

- Drug Discov Today. 2020;25(8):1487–1501. doi:10.1016/j.drudis.2020.05.011
- [19] Hantoushzadeh S, Behzadian A, Mehdi Hasheminejad M, et al. Aspirin administration from early pregnancy versus initiation after 11 weeks of gestation for prevention of pre-eclampsia in high-risk pregnant women: Study protocol for randomized controlled trial. *Int J Reprod Biomed.* 2024;22(1):69–80. Published 2024 Feb 23. doi:10.18502/ijrm.v22i1.15244
- [20] Rolnik DL, Syngelaki A, O’Gorman N, Wright D, Nicolaides KH, Poon LC. Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy. *Am J Obstet Gynecol.* 2024;231(3):342.e1–342.e9. doi:10.1016/j.ajog.2023.12.031
- [21] Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. *Am J Obstet Gynecol.* 2022;226(2S):S1108–S1119. doi:10.1016/j.ajog.2020.08.045 <https://pubmed.ncbi.nlm.nih.gov/>
- [22] D’Antonio F, Khalil A, Rizzo G, et al. Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM.* 2023;5(2):100803. doi:10.1016/j.ajogmf.2022.100803
- [23] Tolcher MC, Sangi-Haghpeykar H, Mendez-Figueroa H, Aagaard KM. Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. *Am J Obstet Gynecol MFM.* 2020;2(4):100184. doi:10.1016/j.ajogmf.2020.100184
- [24] Rolnik DL, Syngelaki A, O’Gorman N, Wright D, Poon LC, Nicolaides KH. ASPRE trial: effects of aspirin on mean arterial blood pressure and uterine artery pulsatility index trajectories in pregnancy. *Ultrasound Obstet Gynecol.* 2023;61(6):691–697. doi:10.1002/uog.26222 <https://pubmed.ncbi.nlm.nih.gov/37058400/>
- [25] Delgado A, Kendle AM, Randis T, et al. Association between Sleep Disordered Breathing and Neonatal Outcomes in Nulliparous Individuals. *Am J Perinatol.* 2024;41(S 01):e2418–e2426. doi:10.1055/a-2115-0147
- [26] Van Doorn R, Mukhtarova N, Flyke IP, et al. Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: A systematic review and meta-analysis. *PLoS One.* 2021;16(3):e0247782. Published 2021 Mar 9. doi:10.1371/journal.pone.0247782
- [27] Amro FH, Blackwell SC, Pedroza C, et al. Aspirin 162 mg versus 81 mg for Preeclampsia Prophylaxis in High-risk Obese Individuals: A Comparative Effectiveness Open Label Randomized Trial (ASPREGO). *Am J Obstet Gynecol.* Published online July 6, 2024. doi:10.1016/j.ajog.2024.0
- [28] Theilen LH, Campbell HD, Mumford SL, et al. Platelet activation and placenta-mediated adverse pregnancy outcomes: an ancillary study to the Effects of Aspirin in Gestation and Reproduction trial. *Am J Obstet Gynecol.* 2020;223(5):741.e1–741.e12. doi:10.1016/j.ajog.2020.05.026
- [29] Xiao Y, Ling Q, Yao M, et al. Aspirin 75 mg to prevent preeclampsia in high-risk pregnancies: a retrospective real-world study in China. *Eur J Med Res.* 2023;28(1):56. Published 2023 Feb 2. doi:10.1186/s40001-023-01024-7
- [30] Pooh RK. First-trimester preterm preeclampsia prediction model for prevention with low-dose aspirin. *J Obstet Gynaecol Res.* 2024;50(5):793–799. doi:10.1111/jog.15908
- [31] Abdi N, Rozrokh A, Alavi A, et al. The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. *J*

Chin Med Assoc. 2020;83(9):852-857. doi:10.1097/JCMA.0000000000000400

- [32] Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention [published correction appears in *Int J Gynaecol Obstet*. 2019 Sep;146(3):390-391. doi: 10.1002/ijgo.12892]. *Int J Gynaecol Obstet*. 2019;145 Suppl 1(Suppl 1):1-33. doi:10.1002/ijgo.12802
- [33] Karunia RI, Purnamayanti A, Prasetyadi FOH. Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia. *J Basic Clin Physiol Pharmacol*. 2020;30(6):j/jbcpp.2019.30.issue-6/jbcpp-2019-0299/jbcpp-2019-0299.xml. Published 2020 Jan 13. doi:10.1515/jbcpp-2019-0299
- [34] Sium AF, Gudu W, Tolu LB, Birara M, Bekele D. Missed opportunity for aspirin prophylaxis for preeclampsia prevention: a cross-sectional study from Sub-Saharan Africa. *AJOG Glob Rep*. 2023;4(1):100295. Published 2023 Dec 4. doi:10.1016/j.xagr.2023.100295
- [35] Boelig RC, Wanees M, Zhan T, Berghella V, Roman A. Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study. *Am J Perinatol*. 2021;38(6):544-552. doi:10.1055/s-0040-1718580
- [36] Sinha N, Singh S, Agarwal M, et al. A Randomized Controlled Study Comparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women. *Cureus*. 2023;15(5):e39752. Published 2023 May 30. doi:10.7759/cureus.39752
- [37] Wright D, Wright A, Tan MY, Nicolaides KH. When to give aspirin to prevent preeclampsia: application of Bayesian decision theory. *Am J Obstet Gynecol*. 2022;226(2S):S1120-S1125. doi:10.1016/j.ajog.2021.10.038
- [38] Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis. *Obstet Gynecol*. 2019;134(3):537-544. doi:10.1097/AOG.0000000000003413